SGT-001

Asset

Delivers a microdystrophin gene to restore muscle dystrophin function and support neuronal nitric oxide synthase activity.

Stage: Clinical, no phase
Modality: Gene therapy
Target: DMD; 1
Indication: 0
Trials: 1
Developer

Indications

1

Duchenne muscular dystrophy
Clinical, no phase, sec.gov, Oct 23, 2020

In the full profile

Targets and what it contains1
Owner and partners1
Evidence for its targets1
Competitors7
Signals1

Every asset’s record: target, stage, trials and the evidence behind it.